Antihormonal to Leukemia--Modified Cytokine Receptor
1 R43 CA63861-1,
This Phase I is designed to test feasibility of developing immunotoxins for human lymphoidleukemia using IL-2 and either 90Y or 131I. There is ample evidence that many cases of humanleukemia are cytokine-dependent. The Principal Investigator has long experience in the study oferythropoietin-dependent erythroleukemia induced by Friend's spleen focus forming virus. Recently,several clinical trials have already established the efficacy of immunotoxin approach in certainmalignancies and other diverse conditions such as autoimmune disorders and graft vs. host diseases.In this application, we will test bioactivity of human recombinant prepare and purify 131I-IL-2, prepareand purify 90Y-IL-2, analyze the radiolabeled IL-2 compounds and test specificity of the compoundsusing cell lines that are dependent on other cytokines. We will also test the effects on primary murineand human T-cells.
Small Business Information at Submission:
Principal Investigator:David Hankins
4853 Cordell Avenue #1407 Bethesda, MD 20814
Number of Employees: